GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Gross Margin %

Ardelyx (Ardelyx) Gross Margin % : 85.23% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Ardelyx's Gross Profit for the three months ended in Dec. 2023 was $29.3 Mil. Ardelyx's Revenue for the three months ended in Dec. 2023 was $34.4 Mil. Therefore, Ardelyx's Gross Margin % for the quarter that ended in Dec. 2023 was 85.23%.


The historical rank and industry rank for Ardelyx's Gross Margin % or its related term are showing as below:

ARDX' s Gross Margin % Range Over the Past 10 Years
Min: 80   Med: 88.64   Max: 98.08
Current: 85.7


During the past 12 years, the highest Gross Margin % of Ardelyx was 98.08%. The lowest was 80.00%. And the median was 88.64%.

ARDX's Gross Margin % is ranked better than
80.27% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs ARDX: 85.70

Ardelyx had a gross margin of 85.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Ardelyx was 0.70% per year.


Ardelyx Gross Margin % Historical Data

The historical data trend for Ardelyx's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Gross Margin % Chart

Ardelyx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.64 98.08 90.10 92.11 85.70

Ardelyx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.84 86.48 84.38 86.36 85.23

Competitive Comparison of Ardelyx's Gross Margin %

For the Biotechnology subindustry, Ardelyx's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Ardelyx's Gross Margin % falls into.



Ardelyx Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Ardelyx's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=106.7 / 124.456
=(Revenue - Cost of Goods Sold) / Revenue
=(124.456 - 17.795) / 124.456
=85.70 %

Ardelyx's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=29.3 / 34.363
=(Revenue - Cost of Goods Sold) / Revenue
=(34.363 - 5.077) / 34.363
=85.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Ardelyx  (NAS:ARDX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ardelyx had a gross margin of 85.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Ardelyx Gross Margin % Related Terms

Thank you for viewing the detailed overview of Ardelyx's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx (Ardelyx) Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Executives
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010